Alicia Morgans, MD, MPH Discusses the Importance of Patient Support Networks During the COVID-19 Pandemic

Video

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about the important role that patient support networks play for those with cancer and the challenge of separating patients from their loved ones during the COVID-19 pandemic.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the survivorship program at Dana-Farber Cancer Institute, about the importance of patient support networks for those with cancer during the COVID-19 pandemic. Morgans highlighted the challenges in separating patients from their loved ones when entering the clinic room, as well as the strength and resilient she saw from her patients during the pandemic.

Transcript:

The pandemic has truly turned the whole world upside down. Whether you work in cancer care, whether you’re a parent, whether you have a job that you now can’t go to regularly, all of us have experienced and been touched by the events from the last year.

Specifically, when it comes to cancer care, I think that it has shown me how incredibly important patient support networks are to them. When we had periods of time in our clinics where we couldn’t let family members come into the clinic room and patients had to be on their own, it was truly heart wrenching. I’m glad that we as healthcare providers are able now to be vaccinated [and can] let family members support the patients that they care about. I think that I never want to learn the lesson again where I have to separate people from their support. I’m just so amazed at how much the people around [those] with cancer do to get people through these experiences. I’m just touched, and I’m happy that we hopefully will not have to do that again.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content